✦ LIBER ✦

Impact of pain relief with fulranumab in the treatment of patients with moderate to severe osteoarthritis pain

✍ Scribed by S. Vallow; P. Sanga; E. Polverejan; S. Wang; K. Kelly; J. Thipphawong

Book ID: 118477279
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 35 KB
Volume: 12
Category: Article
ISSN: 1528-8447
DOI: 10.1016/j.jpain.2011.02.218

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy, safety, and tolerability of fu

Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in treatment of patients with moderate-to-severe osteoarthritis pain

✍ P. Sanga; N. Katz; E. Polverejan; S. Wang; K. Kelly; C. Oh; J. Thipphawong 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 36 KB

Efficacy, safety, and tolerability of fu

Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain

✍ Sanga, Panna; Katz, Nathaniel; Polverejan, Elena; Wang, Steven; Kelly, Kathleen 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 988 KB

Nerve growth factor (NGF) is increased in chronic pain conditions. This study examined analgesic efficacy and safety of fulranumab, a fully human monoclonal anti-NGF antibody, in adults with chronic osteoarthritis pain. Patients (n=466, intent-to-treat) were randomized to receive, in addition to the

Efficacy, safety, and tolerability of fu

Efficacy, safety, and tolerability of fulranumab in treatment of patients with moderate-to-severe, chronic low back pain

✍ P. Sanga; K. Karcher; S. Wang; K. Kelly; C. Oh; J. Thipphawong 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 36 KB

Pain Relief and Tolerability Balance of

Pain Relief and Tolerability Balance of Immediate Release Tapentadol or Oxycodone Treatment for Patients with Moderate to Severe Osteoarthritis or Low Back Pain

✍ Shane Kavanagh; W. Jackie Kwong; Geoffrey C. Hammond; Winnie Nelson; David Upmal 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 343 KB

Erratum to: “Efficacy, safety, and toler

Erratum to: “Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain” [PAIN® 2013;154(10):1910–19]

✍ Sanga, Panna; Katz, Nathaniel; Polverejan, Elena; Wang, Steven; Kelly, Kathleen 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 96 KB

Double-blind, randomized study to evalua

Double-blind, randomized study to evaluate efficacy, and safety of fulranumab in patients with moderate to severe, chronic knee pain from osteoarthritis: interim analysis results

✍ Mayorga, A.; Wang, S.; Wang, S.; Kelly, K.; Thipphawong, J. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 93 KB